Compare CPAY & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPAY | INSM |
|---|---|---|
| Founded | 1986 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.8B | 22.4B |
| IPO Year | 2010 | 2000 |
| Metric | CPAY | INSM |
|---|---|---|
| Price | $406.93 | $129.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 24 |
| Target Price | ★ $382.64 | $201.17 |
| AVG Volume (30 Days) | 408.0K | ★ 1.7M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.59 | N/A |
| EPS | ★ 8.79 | N/A |
| Revenue | ★ $4,528,403,000.00 | N/A |
| Revenue This Year | $18.65 | $182.31 |
| Revenue Next Year | $10.46 | $65.19 |
| P/E Ratio | $46.31 | ★ N/A |
| Revenue Growth | ★ 13.93 | N/A |
| 52 Week Low | $252.84 | $90.39 |
| 52 Week High | $427.46 | $212.75 |
| Indicator | CPAY | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 53.49 | 60.78 |
| Support Level | $401.52 | $122.21 |
| Resistance Level | $423.20 | $137.70 |
| Average True Range (ATR) | 8.31 | 4.50 |
| MACD | -1.78 | -0.23 |
| Stochastic Oscillator | 25.29 | 91.12 |
Corpay Inc is a corporate payments company that helps businesses and consumers manage and pay their expenses. The company offers payment and spend management solutions, including accounts payable automation, cross-border payments, commercial card programs, vehicle payment solutions, and lodging payment services. Its reportable segments are: Corporate Payments, Vehicle Payments, Lodging Payments and Other. The majority of the company's revenue is derived from the Vehicle Payments segment, which helps customers to pay for vehicle related expenses. Geographically, it derives the maximum revenue from the United States and the rest from Brazil, the United Kingdom and other countries.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.